{
  "drugName": "Emgality",
  "setId": "33a147be-233a-40e8-a55e-e40936e28db0",
  "slug": "emgality-33a147b",
  "labeler": "Eli Lilly and Company",
  "label": {
    "genericName": "galcanezumab-gnlm",
    "labelerName": "Eli Lilly and Company",
    "productType": "HUMAN PRESCRIPTION DRUG LABEL",
    "effectiveTime": "20210311",
    "title": "EMGALITY",
    "indicationsAndUsage": "<section class=\"Section\" data-sectioncode=\"34067-9\"><a name=\"s2\"></a><a name=\"section-1\"></a><p></p><h1>1 INDICATIONS AND USAGE</h1><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s3\"></a><a name=\"section-1.1\"></a><p></p><h2>1.1 Migraine</h2><p class=\"First\">EMGALITY is indicated for the preventive treatment of migraine in adults.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s4\"></a><a name=\"section-1.2\"></a><p></p><h2>        1.2 Episodic Cluster Headache</h2><p class=\"First\">         EMGALITY is indicated for the treatment of episodic cluster headache in adults.</p></div></section>",
    "dosageAndAdministration": "<section class=\"Section\" data-sectioncode=\"34068-7\"><a name=\"s5\"></a><a name=\"section-2\"></a><p></p><h1>2 DOSAGE AND ADMINISTRATION</h1><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s6\"></a><a name=\"section-2.1\"></a><p></p><h2>2.1 Recommended Dosing for Migraine</h2><p class=\"First\">The recommended dosage of EMGALITY is 240 mg (two consecutive subcutaneous injections of 120 mg each) once as a loading dose, followed by monthly doses of 120 mg injected subcutaneously.</p><p>If a dose of EMGALITY is missed, administer as soon as possible. Thereafter, EMGALITY can be scheduled monthly from the date of the last dose.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s8\"></a><a name=\"section-2.2\"></a><p></p><h2>        2.2 Recommended Dosing for Episodic Cluster Headache</h2><p class=\"First\">         The recommended dosage of EMGALITY is 300 mg (three consecutive subcutaneous injections of 100 mg each) at the onset of the cluster period, and then monthly until the end of the cluster period.</p><p>         If a dose of EMGALITY is missed during a cluster period, administer as soon as possible. Thereafter, EMGALITY can be scheduled monthly from the date of the last dose until the end of the cluster period.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s9\"></a><a name=\"section-2.3\"></a><p></p><h2>2.3 Important Administration Instructions</h2><p class=\"First\">EMGALITY is for subcutaneous use only.</p><p>EMGALITY is intended for patient self-administration. Prior to use, provide proper training to patients and/or caregivers on how to prepare and administer EMGALITY using the single-dose prefilled pen or single-dose prefilled syringe, including aseptic technique <span class=\"Italics\">[see How Supplied/Storage and Handling (<a href=\"#s55\">16.2</a>) and Instructions for Use]</span>:</p><ul class=\"Disc\"><li>Protect EMGALITY from direct sunlight.</li><li>Prior to subcutaneous administration, allow EMGALITY to sit at room temperature for 30 minutes. Do not warm by using a heat source such as hot water or a microwave.</li><li>Do not shake the product.</li><li>Inspect EMGALITY visually for particulate matter and discoloration prior to administration, whenever solution and container permit <span class=\"Italics\">[see Dosage Forms and Strengths (<a href=\"#s10\">3</a>) and How Supplied/Storage and Handling (<a href=\"#s54\">16.1</a>)]</span>. Do not use EMGALITY if it is cloudy or there are visible particles.</li><li>Administer EMGALITY in the abdomen, thigh, back of the upper arm, or buttocks subcutaneously. Do not inject into areas where the skin is tender, bruised, red, or hard.</li><li>Both the prefilled pen and prefilled syringe are single-dose and deliver the entire contents.</li></ul></div></section>",
    "dosageFormsAndStrengths": "<section class=\"Section\" data-sectioncode=\"43678-2\"><a name=\"s10\"></a><a name=\"section-3\"></a><p></p><h1>3 DOSAGE FORMS AND STRENGTHS</h1><p class=\"First\">EMGALITY is a sterile clear to opalescent, colorless to slightly yellow to slightly brown solution available as follows:</p><ul class=\"Disc\"><li>Injection: 120 mg/mL in a single-dose prefilled pen</li><li>Injection: 120 mg/mL in a single-dose prefilled syringe</li><li>Injection: 100 mg/mL in a single-dose prefilled syringe</li></ul></section>",
    "warningsAndPrecautions": "<section class=\"Section\" data-sectioncode=\"43685-7\"><a name=\"s12\"></a><a name=\"section-5\"></a><p></p><h1>5 WARNINGS AND PRECAUTIONS</h1><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s13\"></a><a name=\"section-5.1\"></a><p></p><h2>5.1 Hypersensitivity Reactions</h2><p class=\"First\">         Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with EMGALITY in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of EMGALITY and initiate appropriate therapy <span class=\"Italics\">[see Contraindications (<a href=\"#s11\">4</a>), Adverse Reactions (<a href=\"#s15\">6.1</a>), and Patient Counseling Information (<a href=\"#s56\">17</a>)]</span>. Hypersensitivity reactions can occur days after administration and may be prolonged.</p></div></section>",
    "adverseReactions": "<section class=\"Section\" data-sectioncode=\"34084-4\"><a name=\"s14\"></a><a name=\"section-6\"></a><p></p><h1>6 ADVERSE REACTIONS</h1><p class=\"First\">The following clinically significant adverse reactions are described elsewhere in the labeling:</p><ul class=\"Disc\"><li>Hypersensitivity Reactions <span class=\"Italics\">[see Contraindications (<a href=\"#s11\">4</a>) and Warnings and Precautions (<a href=\"#s13\">5.1</a>)]</span></li></ul><div class=\"Section\" data-sectioncode=\"90374-0\"><a name=\"s15\"></a><a name=\"section-6.1\"></a><p></p><h2>6.1 Clinical Trials Experience</h2><p class=\"First\">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in clinical trials of another drug and may not reflect the rates observed in clinical practice.</p><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s16\"></a><a name=\"section-6.1.1\"></a><p></p><p class=\"First\"><span class=\"Underline\">Migraine</span></p><p>The safety of EMGALITY has been evaluated in 2586 patients with migraine who received at least one dose of EMGALITY, representing 1487 patient-years of exposure. Of these, 1920 patients were exposed to EMGALITY once monthly for at least 6 months, and 526 patients were exposed for 12 months.</p><p>In placebo-controlled clinical studies (Studies 1, 2, and 3), 705 patients received at least one dose of EMGALITY 120 mg once monthly, and 1451 patients received placebo, during 3 months or 6 months of double-blind treatment <span class=\"Italics\">[see Clinical Studies (<a href=\"#s49\">14.1</a>)]</span>. Of the EMGALITY-treated patients, approximately 85% were female, 77% were white, and the mean age was 41 years at study entry.</p><p>The most common adverse reaction was injection site reactions. In Studies 1, 2, and 3, 1.8% of patients discontinued double-blind treatment because of adverse events. <a href=\"#t1\">Table 1</a> summarizes the adverse reactions that occurred within up to 6 months of treatment in the migraine studies.</p><a name=\"t1\"></a><table width=\"100%\"><caption><span>Table 1: Adverse Reactions Occurring in Adults with Migraine with an Incidence of at least 2% for EMGALITY and at least 2% Greater than Placebo (up to 6 Months of Treatment) in Studies 1, 2, and 3</span></caption><col align=\"left\" width=\"40.753%\"/><col align=\"left\" width=\"29.623%\"/><col align=\"left\" width=\"29.623%\"/><tfoot><tr class=\"First Last\"><td align=\"left\" colspan=\"3\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">a</span> Injection site reactions include multiple related adverse event terms, such as injection site pain, injection site reaction, injection site erythema, and injection site pruritus.</p></td></tr></tfoot><tbody class=\"Headless\"><tr class=\"First\"><td align=\"left\" class=\"Botrule Lrule Rrule Toprule\" valign=\"top\"><br/><span class=\"Bold\">Adverse Reaction</span></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">EMGALITY 120 mg</span><br/><span class=\"Bold\">Monthly</span><br/><span class=\"Bold\">(N=705)</span><br/><span class=\"Bold\">%</span></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">Placebo</span><br/><span class=\"Bold\">Monthly</span><br/><span class=\"Bold\">(N=1451)</span><br/><span class=\"Bold\">%</span></td></tr><tr class=\"Last\"><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Injection site reactions<span class=\"Sup\">a</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">18</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">13</td></tr></tbody></table></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s17\"></a><a name=\"section-6.1.2\"></a><p></p><p class=\"First\"><span class=\"Underline\">Episodic Cluster Headache</span></p><p>EMGALITY was studied for up to 2 months in a placebo-controlled trial in patients with episodic cluster headache (Study 4) <span class=\"Italics\">[see Clinical Studies (<a href=\"#s52\">14.2</a>)]</span>. A total of 106 patients were studied (49 on EMGALITY and 57 on placebo). Of the EMGALITY-treated patients, approximately 84% were male, 88% were white, and the mean age was 47 years at study entry. Two EMGALITY-treated patients discontinued double-blind treatment because of adverse events.</p><p>Overall, the safety profile observed in patients with episodic cluster headache treated with EMGALITY 300 mg monthly is consistent with the safety profile in migraine patients.</p></div></div><div class=\"Section\" data-sectioncode=\"88830-5\"><a name=\"s18\"></a><a name=\"section-6.2\"></a><p></p><h2>6.2 Immunogenicity</h2><p class=\"First\">As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease.</p><p>For these reasons, comparison of the incidence of antibodies to galcanezumab-gnlm in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.</p><p>The immunogenicity of EMGALITY has been evaluated using an in vitro immunoassay for the detection of binding anti-galcanezumab-gnlm antibodies. For patients whose sera tested positive in the screening immunoassay, an in vitro ligand-binding immunoassay was performed to detect neutralizing antibodies.</p><p>In controlled studies with EMGALITY up to 6 months (Study 1, Study 2, and Study 3), the incidence of anti-galcanezumab-gnlm antibody development was 4.8% (33/688) in patients receiving EMGALITY once monthly (32 out of 33 of whom had <span class=\"Italics\">in vitro</span> neutralizing activity). With 12 months of treatment in an open-label study, up to 12.5% (16/128) of EMGALITY-treated patients developed anti-galcanezumab-gnlm antibodies, most of whom tested positive for neutralizing antibodies.</p><p>Although anti-galcanezumab-gnlm antibody development was not found to affect the pharmacokinetics, safety or efficacy of EMGALITY in these patients, the available data are too limited to make definitive conclusions.</p></div><div class=\"Section\" data-sectioncode=\"90375-7\"><a name=\"s18a\"></a><a name=\"section-6.3\"></a><p></p><h2>6.3 Postmarketing Experience</h2><p class=\"First\">The following adverse reactions have been identified during post-approval use of EMGALITY. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to EMGALITY exposure.</p><p><span class=\"Italics\">Immune System Disorders</span>— Anaphylaxis, angioedema <span class=\"Italics\">[see Contraindications (<a href=\"#s11\">4</a>) and Warnings and Precautions (<a href=\"#s13\">5.1</a>)]</span>.</p><p><span class=\"Italics\">Skin and Subcutaneous Tissue Disorders</span>— Rash.</p></div></section>",
    "clinicalPharmacology": "<section class=\"Section\" data-sectioncode=\"34090-1\"><a name=\"s31\"></a><a name=\"section-9\"></a><p></p><h1>12 CLINICAL PHARMACOLOGY</h1><div class=\"Section\" data-sectioncode=\"43679-0\"><a name=\"s32\"></a><a name=\"section-9.1\"></a><p></p><h2>12.1 Mechanism of Action</h2><p class=\"First\">Galcanezumab-gnlm is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.</p></div><div class=\"Section\" data-sectioncode=\"43681-6\"><a name=\"s33\"></a><a name=\"section-9.2\"></a><p></p><h2>12.2 Pharmacodynamics</h2><p class=\"First\">There are no relevant data on the pharmacodynamic effects of galcanezumab-gnlm.</p></div><div class=\"Section\" data-sectioncode=\"43682-4\"><a name=\"s34\"></a><a name=\"section-9.3\"></a><p></p><h2>12.3 Pharmacokinetics</h2><p class=\"First\">Galcanezumab-gnlm exhibits linear pharmacokinetics and exposure increases proportionally with doses between 1 and 600 mg.</p><p>A loading dose of 240 mg achieved the serum galcanezumab-gnlm steady-state concentration after the first dose. A dose of 300 mg monthly would achieve steady-state concentration after the fourth dose. The time to maximum concentration is 5 days, and the elimination half-life is 27 days.</p><p>There was no difference in pharmacokinetic parameters between healthy volunteers, patients with episodic or chronic migraine, and patients with episodic cluster headache.</p><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s35\"></a><a name=\"section-9.3.1\"></a><p></p><p class=\"First\"><span class=\"Underline\">Absorption</span></p><p>Following a subcutaneous dose of galcanezumab-gnlm, the time to maximum concentration was about 5 days.</p><p>Injection site location did not significantly influence the absorption of galcanezumab-gnlm.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s36\"></a><a name=\"section-9.3.2\"></a><p></p><p class=\"First\"><span class=\"Underline\">Distribution</span></p><p>The apparent volume of distribution (V/F) of galcanezumab-gnlm was 7.3 L (34% Inter Individual Variability [IIV]).</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s37\"></a><a name=\"section-9.3.3\"></a><p></p><p class=\"First\"><span class=\"Underline\">Metabolism and Elimination</span></p><p>Galcanezumab-gnlm is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.</p><p>The apparent clearance (CL/F) of galcanezumab-gnlm was 0.008 L/h and the elimination half-life of galcanezumab was approximately 27 days.</p><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s38\"></a><a name=\"section-9.3.3.1\"></a><p></p><p class=\"First\">Specific Populations</p><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s39\"></a><a name=\"section-9.3.3.1.1\"></a><p></p><p class=\"First\"><span class=\"Italics\">Age, Sex, Weight, Race, Ethnicity</span></p><p>The pharmacokinetics of galcanezumab-gnlm were not affected by age, sex, race, subtypes of migraine spectrum (episodic or chronic migraine), or headache diagnosis (migraine vs. episodic cluster headache) based on a population pharmacokinetics analysis. Body weight has no clinically relevant effect on the pharmacokinetics of galcanezumab-gnlm.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s40\"></a><a name=\"section-9.3.3.1.2\"></a><p></p><p class=\"First\"><span class=\"Italics\">Patients with Renal or Hepatic Impairment</span></p><p>Renal and hepatic impairment are not expected to affect the pharmacokinetics of galcanezumab-gnlm. Population pharmacokinetic analysis of integrated data from the galcanezumab-gnlm clinical studies revealed that creatinine clearance did not affect the pharmacokinetics of galcanezumab-gnlm in patients with mild or moderate renal impairment. Patients with severe renal impairment (creatinine clearance &lt;30 mL/min) have not been studied. Based on a population PK analysis, bilirubin concentration did not significantly influence the CL/F of galcanezumab-gnlm.</p><p>No dedicated clinical studies were conducted to evaluate the effect of hepatic impairment or renal impairment on the pharmacokinetics of galcanezumab-gnlm.</p></div></div></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s41\"></a><a name=\"section-9.3.4\"></a><p></p><p class=\"First\"><span class=\"Underline\">Drug Interaction Studies</span></p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s42\"></a><a name=\"section-9.3.5\"></a><p></p><p class=\"First\"><span class=\"Italics\">P450 Enzymes</span></p><p>Galcanezumab-gnlm is not metabolized by cytochrome P450 enzymes; therefore, interactions with concomitant medications that are substrates, inducers, or inhibitors of cytochrome P450 enzymes are unlikely.</p></div></div></section>",
    "clinicalStudies": "<section class=\"Section\" data-sectioncode=\"34092-7\"><a name=\"s48\"></a><a name=\"section-11\"></a><p></p><h1>14 CLINICAL STUDIES</h1><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s49\"></a><a name=\"section-11.1\"></a><p></p><h2>14.1 Migraine</h2><p class=\"First\">The efficacy of EMGALITY was evaluated as a preventive treatment of episodic or chronic migraine in three multicenter, randomized, double-blind, placebo-controlled studies: two 6-month studies in patients with episodic migraine (Studies 1 and 2) and one 3-month study in patients with chronic migraine (Study 3).</p><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s50\"></a><a name=\"section-11.1.1\"></a><p></p><p class=\"First\"><span class=\"Underline\">Episodic Migraine</span></p><p>Study 1 (NCT02614183) and Study 2 (NCT02614196) included adults with a history of episodic migraine (4 to 14 migraine days per month). All patients were randomized in a 1:1:2 ratio to receive once-monthly subcutaneous injections of EMGALITY 120 mg, EMGALITY 240 mg, or placebo. All patients in the 120 mg EMGALITY group received an initial 240 mg loading dose. Patients were allowed to use acute headache treatments, including migraine-specific medications (i.e., triptans, ergotamine derivatives), NSAIDs, and acetaminophen during the study.</p><p>The studies excluded patients on any other migraine preventive treatment, patients with medication overuse headache, patients with ECG abnormalities compatible with an acute cardiovascular event and patients with a history of stroke, myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass grafting, deep vein thrombosis, or pulmonary embolism within 6 months of screening.</p><p>The primary efficacy endpoint for Studies 1 and 2 was the mean change from baseline in the number of monthly migraine headache days over the 6-month treatment period. Key secondary endpoints included response rates (the mean percentages of patients reaching at least 50%, 75%, and 100% reduction from baseline in the number of monthly migraine headache days over the 6-month treatment period), the mean change from baseline in the number of monthly migraine headache days with use of any acute headache medication during the 6-month treatment period, and the impact of migraine on daily activities, as assessed by the mean change from baseline in the average Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v2.1) Role Function-Restrictive domain score during the last 3 months of treatment (Months 4 to 6). Scores are scaled from 0 to 100, with higher scores indicating less impact of migraine on daily activities.</p><p>In Study 1, a total of 858 patients (718 females, 140 males) ranging in age from 18 to 65 years, were randomized. A total of 703 patients completed the 6-month double-blind phase. In Study 2, a total of 915 patients (781 female, 134 male) ranging in age from 18 to 65 years, were randomized. A total of 785 patients completed the 6-month double-blind phase. In Study 1 and Study 2, the mean migraine frequency at baseline was approximately 9 migraine days per month, and was similar across treatment groups.</p><p>EMGALITY 120 mg demonstrated statistically significant improvements for efficacy endpoints compared to placebo over the 6-month period, as summarized in <a href=\"#t2\">Table 2</a>. EMGALITY treatment with the 240 mg once-monthly dose showed no additional benefit over the EMGALITY 120 mg once-monthly dose.</p><a name=\"t2\"></a><table width=\"100%\"><caption><span>Table 2: Efficacy Endpoints in Studies 1 and 2</span></caption><col align=\"left\" width=\"38.460%\"/><col align=\"left\" width=\"15.380%\"/><col align=\"left\" width=\"15.380%\"/><col align=\"left\" width=\"15.380%\"/><col align=\"left\" width=\"15.400%\"/><tfoot><tr class=\"First\"><td align=\"left\" colspan=\"5\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">a</span> p&lt;0.001</p></td></tr><tr class=\"Last\"><td align=\"left\" colspan=\"5\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">b</span> N = 189 for EMGALITY 120 mg and N = 377 for placebo in Study 1; N = 213 for EMGALITY 120 mg and N = 396 for placebo in Study 2.</p></td></tr></tfoot><tbody class=\"Headless\"><tr class=\"First\"><td align=\"left\" class=\"Botrule Lrule Rrule Toprule\" rowspan=\"2\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule Toprule\" colspan=\"2\" valign=\"top\"><span class=\"Bold\">Study 1</span></td><td align=\"center\" class=\"Botrule Rrule Toprule\" colspan=\"2\" valign=\"top\"><span class=\"Bold\">Study 2</span></td></tr><tr><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"><span class=\"Bold\">EMGALITY</span><br/><span class=\"Bold\">120 mg</span><br/><span class=\"Bold\">N = 210</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"><span class=\"Bold\">Placebo</span><br/><br/><span class=\"Bold\">N = 425</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"><span class=\"Bold\">EMGALITY</span><br/><span class=\"Bold\">120 mg</span><br/><span class=\"Bold\">N = 226</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"><span class=\"Bold\">Placebo</span><br/><br/><span class=\"Bold\">N = 450</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" colspan=\"5\" valign=\"top\"><span class=\"Bold\">Monthly Migraine Headache Days (over Months 1 to 6)</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">    Baseline migraine headache days</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">9.2</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">9.1</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">9.1</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">9.2</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">    Mean change from baseline</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-4.7</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-2.8</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-4.3</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-2.3</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">    Difference from placebo<span class=\"Sup\">a</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-1.9</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-2.0</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" colspan=\"5\" valign=\"top\"><span class=\"Bold\">≥50% Migraine Headache Days Responders (over Months 1 to 6)</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">    % Responders<span class=\"Sup\">a</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">62%</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">39%</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">59%</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">36%</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" colspan=\"5\" valign=\"top\"><span class=\"Bold\">≥75% Migraine Headache Days Responders (over Months 1 to 6)</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">    % Responders<span class=\"Sup\">a</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">39%</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">19%</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">34%</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">18%</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" colspan=\"5\" valign=\"top\"><span class=\"Bold\">100% Migraine Headache Days Responders (over Months 1 to 6)</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">    % Responders<span class=\"Sup\">a</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">16%</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">6%</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">12%</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">6%</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" colspan=\"5\" valign=\"top\"><span class=\"Bold\">Monthly Migraine Headache Days that Acute Medication was Taken (over Months 1 to 6)</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">    Mean change from baseline (days)<span class=\"Sup\">a</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-4.0</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-2.2</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-3.7</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-1.9</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" colspan=\"5\" valign=\"top\"><span class=\"Bold\">MSQ Role Function-Restrictive Domain Score (over Months 4 to 6)</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">    Baseline</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">51.4</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">52.9</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">52.5</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">51.4</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">    Mean change from baseline<span class=\"Sup\">b</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">32.4</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">24.7</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">28.5</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">19.7</td></tr><tr class=\"Last\"><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">    Difference from placebo<span class=\"Sup\">a</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">7.7</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">8.8</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td></tr></tbody></table><p class=\"MultiMediaCaption\"><a name=\"fig1\"></a><span class=\"Bold\">Figure 1: Change from Baseline in Monthly Migraine Headache Days in Study 1</span><span class=\"Bold\"><span class=\"Sup\">a</span></span></p><div class=\"Figure\"><a name=\"f01\"></a><img alt=\"Figure 1\n\" src=\"emgality-pi-f1-v1.jpg\"/></div><p><span class=\"Sup\">a</span> Least-square means and 95% confidence intervals are presented.<br/><br/></p><p class=\"MultiMediaCaption\"><a name=\"fig2\"></a><span class=\"Bold\">Figure 2: Change from Baseline in Monthly Migraine Headache Days in Study 2</span><span class=\"Bold\"><span class=\"Sup\">a</span></span></p><div class=\"Figure\"><a name=\"f02\"></a><img alt=\"Figure 2\n\" src=\"emgality-pi-f2-v1.jpg\"/></div><p><span class=\"Sup\">a</span> Least-square means and 95% confidence intervals are presented.</p><p><a href=\"#fig3\">Figure 3</a> shows the distribution of change from baseline in the mean number of monthly migraine headache days in bins of 2 days, by treatment group, in Study 1. A treatment benefit over placebo for EMGALITY is seen across a range of changes from baseline in monthly migraine headache days.<br/><br/></p><p class=\"MultiMediaCaption\"><a name=\"fig3\"></a><span class=\"Bold\">Figure 3: Distribution of Change from Baseline in Mean Monthly Migraine Headache Days over Months 1 to 6 by Treatment Group in Study 1</span></p><div class=\"Figure\"><a name=\"f03\"></a><img alt=\"Figure 3\n\" src=\"emgality-pi-f3-v1.jpg\"/></div><p><a href=\"#fig4\">Figure 4</a> shows the distribution of change from baseline in the mean number of monthly migraine headache days in bins of 2 days, by treatment group, in Study 2. A treatment benefit over placebo for EMGALITY is seen across a range of changes from baseline in monthly migraine headache days.<br/><br/></p><p class=\"MultiMediaCaption\"><a name=\"fig4\"></a><span class=\"Bold\">Figure 4: Distribution of Change from Baseline in Mean Monthly Migraine Headache Days over Months 1 to 6 by Treatment Group in Study 2</span></p><div class=\"Figure\"><a name=\"f04\"></a><img alt=\"Figure 4\n\" src=\"emgality-pi-f4-v1.jpg\"/></div></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s51\"></a><a name=\"section-11.1.2\"></a><p></p><p class=\"First\"><span class=\"Underline\">Chronic Migraine</span></p><p>Study 3 (NCT02614261) included adults with a history of chronic migraine (≥15 headache days per month with ≥8 migraine days per month). All patients were randomized in a 1:1:2 ratio to receive once-monthly subcutaneous injections of EMGALITY 120 mg, EMGALITY 240 mg, or placebo over a 3-month treatment period. All patients in the 120 mg EMGALITY group received an initial 240 mg loading dose.</p><p>Patients were allowed to use acute headache treatments including migraine-specific medications (i.e., triptans, ergotamine derivatives), NSAIDs, and acetaminophen. A subset of patients (15%) was allowed to use one concomitant migraine preventive medication. Patients with medication overuse headache were allowed to enroll.</p><p>The study excluded patients with ECG abnormalities compatible with an acute cardiovascular event, and patients with a history of stroke, myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass grafting, deep vein thrombosis, or pulmonary embolism within 6 months of screening.</p><p>The primary endpoint was the mean change from baseline in the number of monthly migraine headache days over the 3-month treatment period. The secondary endpoints were response rates (the mean percentages of patients reaching at least 50%, 75% and 100% reduction from baseline in the number of monthly migraine headache days over the 3-month treatment period), the mean change from baseline in the number of monthly migraine headache days with use of any acute headache medication during the 3-month treatment period, and the impact of migraine on daily activities as assessed by the mean change from baseline in the MSQ v2.1 Role Function-Restrictive domain score at Month 3. Scores are scaled from 0 to 100, with higher scores indicating less impact of migraine on daily activities.</p><p>In Study 3, a total of 1113 patients (946 female, 167 male) ranging in age from 18 to 65 years, were randomized. A total of 1037 patients completed the 3-month double-blind phase. The mean number of monthly migraine headache days at baseline was approximately 19.</p><p>EMGALITY 120 mg demonstrated statistically significant improvement for the mean change from baseline in the number of monthly migraine headache days over the 3-month treatment period, and in the mean percentage of patients reaching at least 50% reduction from baseline in the number of monthly migraine headache days over the 3-month treatment period, as summarized in <a href=\"#t3\">Table 3</a>. EMGALITY treatment with the 240 mg once-monthly dose showed no additional benefit over the EMGALITY 120 mg once-monthly dose.</p><a name=\"t3\"></a><table width=\"100%\"><caption><span>Table 3: Efficacy Endpoints in Study 3</span></caption><col align=\"left\" width=\"39.154%\"/><col align=\"left\" width=\"30.423%\"/><col align=\"left\" width=\"30.423%\"/><tfoot><tr class=\"First Last\"><td align=\"left\" colspan=\"3\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">a</span> p&lt;0.001</p></td></tr></tfoot><tbody class=\"Headless\"><tr class=\"First\"><td align=\"left\" class=\"Botrule Lrule Rrule Toprule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">EMGALITY</span><br/><span class=\"Bold\">120 mg</span><br/><span class=\"Bold\">N = 273</span></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">Placebo</span><br/><br/><span class=\"Bold\">N =538</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" colspan=\"3\" valign=\"top\"><span class=\"Bold\">Monthly Migraine Headache Days (over Months 1 to 3)</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">    Baseline migraine headache days</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">19.4</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">19.6</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">    Mean change from baseline</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-4.8</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-2.7</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">    Difference from placebo<span class=\"Sup\">a</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-2.1</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" colspan=\"3\" valign=\"top\"><span class=\"Bold\">≥50% Migraine Headache Days Responders (over Months 1 to 3)</span></td></tr><tr class=\"Last\"><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">    % Responders<span class=\"Sup\">a</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">28%</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">15%</td></tr></tbody></table><p>Study 3 utilized a sequential testing procedure to control the Type-I error rate for the multiple secondary endpoints. Once a secondary endpoint failed to reach the required level for statistical significance, formal hypothesis testing was terminated for subsequent endpoints, and p-values were considered nominal only. In Study 3, EMGALITY 120 mg was not significantly better than placebo for the proportion of patients with ≥75% or 100% reduction in migraine headache days. Patients treated with EMGALITY 120 mg showed a nominally greater reduction in the number of monthly migraine headache days that acute medication was taken (-4.7 for EMGALITY 120 mg vs. -2.2 for placebo; nominal p-value &lt;0.001), and the mean change from baseline in the MSQ Role Function-Restrictive Domain score at Month 3 was nominally greater in patients treated with EMGALITY 120 mg than in patients on placebo (21.8 for EMGALITY 120 mg vs. 16.8 for placebo; nominal p-value &lt;0.001).<br/><br/></p><p class=\"MultiMediaCaption\"><a name=\"fig5\"></a><span class=\"Bold\">Figure 5: Change from Baseline in Monthly Migraine Headache Days in Study 3</span><span class=\"Bold\"><span class=\"Sup\">a</span></span></p><div class=\"Figure\"><a name=\"f05\"></a><img alt=\"Figure 6\n\" src=\"emgality-pi-f5-v1.jpg\"/></div><p><span class=\"Sup\">a</span> Least-square means and 95% confidence intervals are presented.</p><p><a href=\"#fig6\">Figure 6</a> shows the distribution of change from baseline in the mean number of monthly migraine headache days for the 3-month study period in bins of 3 days by treatment group. A treatment benefit over placebo for EMGALITY is seen across a range of changes from baseline in monthly migraine headache days.<br/><br/></p><p class=\"MultiMediaCaption\"><a name=\"fig6\"></a><span class=\"Bold\">Figure 6: Distribution of Change from Baseline in Mean Monthly Migraine Headache Days over Months 1 to 3 by Treatment Group in Study 3</span></p><div class=\"Figure\"><a name=\"f06\"></a><img alt=\"Figure 6\n\" src=\"emgality-pi-f6-v1.jpg\"/></div></div></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s52\"></a><a name=\"section-11.2\"></a><p></p><h2>14.2 Episodic Cluster Headache</h2><p class=\"First\">The efficacy of EMGALITY was evaluated for the treatment of episodic cluster headache in a randomized, 8-week, double-blind, placebo-controlled study (Study 4).</p><p>Study 4 (NCT02397473) included adults who met the International Classification of Headache Disorders 3<span class=\"Sup\">rd</span> edition (beta version) diagnostic criteria for episodic cluster headache and had a maximum of 8 attacks per day, a minimum of one attack every other day, and at least 4 attacks during the prospective 7-day baseline period. All patients were randomized in a 1:1 ratio to receive once-monthly subcutaneous injections of EMGALITY 300 mg or placebo. Patients were allowed to use certain specified acute/abortive cluster headache treatments, including triptans, oxygen, acetaminophen, and NSAIDs during the study.</p><p>The study excluded patients on other treatments intended to reduce the frequency of cluster headache attacks; patients with medication overuse headache; patients with ECG abnormalities compatible with an acute cardiovascular event or conduction delay; and patients with a history of myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass grafting, deep vein thrombosis, or pulmonary embolism within 6 months of screening. In addition, patients with any history of stroke, intracranial or carotid aneurysm, intracranial hemorrhage, or vasospastic angina; clinical evidence of peripheral vascular disease; or diagnosis of Raynaud’s disease were excluded.</p><p>The primary efficacy endpoint for Study 4 was the mean change from baseline in weekly cluster headache attack frequency across Weeks 1 to 3. A secondary endpoint was the percentage of patients who achieved a response (defined as a reduction from baseline of 50% or greater in the weekly cluster headache attack frequency) at Week 3.</p><p>In Study 4, a total of 106 patients (88 males, 18 females) ranging in age from 19 to 65 years were randomized and treated. A total of 90 patients completed the 8-week double-blind phase. In the prospective baseline phase, the mean number of weekly cluster headache attacks was 17.5, and was similar across treatment groups.</p><p>EMGALITY 300 mg demonstrated statistically significant improvements for efficacy endpoints compared to placebo, as summarized in <a href=\"#t4\">Table 4</a>.</p><a name=\"t4\"></a><table width=\"100%\"><caption><span>Table 4: Efficacy Endpoints in Study 4</span></caption><col align=\"left\" width=\"41.733%\"/><col align=\"left\" width=\"29.967%\"/><col align=\"left\" width=\"28.300%\"/><tbody class=\"Headless\"><tr class=\"First\"><td align=\"left\" class=\"Botrule Lrule Rrule Toprule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">EMGALITY</span><br/><span class=\"Bold\">300 mg</span><br/><span class=\"Bold\">N = 49</span></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">Placebo</span><br/><br/><span class=\"Bold\">N = 57</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" colspan=\"3\" valign=\"top\"><span class=\"Bold\">Mean Reduction in Weekly Cluster Headache Attack Frequency (over Weeks 1 to 3)</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">    Prospective Baseline Cluster Headache Attack Frequency</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">17.8</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">17.3</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">    Mean change from baseline</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-8.7</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-5.2</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">    Difference from placebo</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-3.5</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">    p-value</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0.036</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" colspan=\"3\" valign=\"top\"><span class=\"Bold\">≥50% Weekly Cluster Headache Attack Frequency Responders (at Week 3)</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">    % Responders</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">71.4%</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">52.6%</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">    Difference from placebo</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">18.8%</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td></tr><tr class=\"Last\"><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">    p-value</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0.046</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td></tr></tbody></table><p class=\"MultiMediaCaption\"><a name=\"fig7\"></a><span class=\"Bold\">Figure 7: Mean Change in Weekly Cluster Headache Attack Frequency over Weeks 1 to 3 in Study 4<span class=\"Sup\">a</span></span></p><div class=\"Figure\"><a name=\"f07\"></a><img alt=\"Figure 7\n\" src=\"emgality-pi-f7-v2.jpg\"/></div><p><span class=\"Sup\">a</span> Abbreviations: BL = baseline; LS = least square; SE = standard error.</p><p><a href=\"#fig8\">Figure 8</a> shows the distribution of the average percent change from baseline in weekly cluster headache attack frequency across Weeks 1 to 3 in bins of 25%, by treatment group, in Study 4.<br/><br/></p><p class=\"MultiMediaCaption\"><a name=\"fig8\"></a><span class=\"Bold\">Figure 8: Distribution of the Average Percent Change from Baseline in Weekly Cluster Headache Attack Frequency over Weeks 1 to 3 in Study 4</span><span class=\"Bold\"><span class=\"Sup\">a</span></span></p><div class=\"Figure\"><a name=\"f08\"></a><img alt=\"Figure 8\n\" src=\"emgality-pi-f8-v2.jpg\"/></div><p><span class=\"Sup\">a</span> N = number of intent to treat patients with non-missing average percentage change from baseline in weekly cluster headache attack frequency over weeks 1 to 3.</p></div></section>",
    "howSupplied": "<section class=\"Section\" data-sectioncode=\"34069-5\"><a name=\"s54\"></a><a name=\"section-12.1\"></a><p></p><h2>16.1 How Supplied</h2><p class=\"First\">EMGALITY (galcanezumab-gnlm) injection is a sterile, preservative-free, clear to opalescent, colorless to slightly yellow to slightly brown solution for subcutaneous administration.</p><p>EMGALITY is not made with natural rubber latex.</p><p>EMGALITY is supplied as follows:</p><table width=\"100%\"><col align=\"left\" width=\"42.467%\"/><col align=\"left\" width=\"28.767%\"/><col align=\"left\" width=\"28.767%\"/><tbody class=\"Headless\"><tr class=\"First\"><td align=\"left\" class=\"Botrule Lrule Rrule Toprule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">Pack Size</span></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">NDC</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" colspan=\"3\" valign=\"top\"><span class=\"Bold\">Prefilled pen</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">120 mg/mL single-dose</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">Carton of 1</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0002-1436-11</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">120 mg/mL single-dose</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">Carton of 2</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0002-1436-27</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" colspan=\"3\" valign=\"top\"><span class=\"Bold\">Prefilled syringe</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">100 mg/mL single-dose</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">Carton of 3</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0002-3115-09</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" colspan=\"3\" valign=\"top\"> </td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">120 mg/mL single-dose</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">Carton of 1</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0002-2377-11</td></tr><tr class=\"Last\"><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">120 mg/mL single-dose</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">Carton of 2</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0002-2377-27</td></tr></tbody></table></section>",
    "useInSpecificPopulations": "<section class=\"Section\" data-sectioncode=\"43684-0\"><a name=\"s19\"></a><a name=\"section-7\"></a><p></p><h1>8 USE IN SPECIFIC POPULATIONS</h1><div class=\"Section\" data-sectioncode=\"42228-7\"><a name=\"s20\"></a><a name=\"section-7.1\"></a><p></p><h2>8.1 Pregnancy</h2><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s21\"></a><a name=\"section-7.1.1\"></a><p></p><p class=\"First\"><span class=\"Underline\">Pregnancy Exposure Registry</span></p><p>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to EMGALITY during pregnancy. Healthcare providers are encouraged to register pregnant patients, or pregnant women may enroll themselves in the registry by calling 1-833-464-4724 or by contacting the company at www.migrainepregnancyregistry.com.</p><p><span class=\"Underline\">Risk Summary</span></p><p>There are no adequate data on the developmental risk associated with the use of EMGALITY in pregnant women. Administration of galcanezumab-gnlm to rats and rabbits during the period of organogenesis or to rats throughout pregnancy and lactation at plasma exposures greater than that expected clinically did not result in adverse effects on development <span class=\"Italics\">(see Animal Data)</span>.</p><p>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% - 4% and 15% - 20%, respectively. The estimated rate of major birth defects (2.2% - 2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s22\"></a><a name=\"section-7.1.2\"></a><p></p><p class=\"First\"><span class=\"Underline\">Clinical Considerations</span></p><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s23\"></a><a name=\"section-7.1.2.1\"></a><p></p><p class=\"First\"><span class=\"Italics\">Disease-Associated Maternal and/or Embryo/Fetal Risk</span></p><p>Published data have suggested that women with migraine may be at increased risk of preeclampsia during pregnancy.</p></div></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s24\"></a><a name=\"section-7.1.3\"></a><p></p><p class=\"First\"><span class=\"Underline\">Data</span></p><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s25\"></a><a name=\"section-7.1.3.1\"></a><p></p><p class=\"First\"><span class=\"Italics\">Animal Data</span></p><p>When galcanezumab-gnlm was administered to female rats by subcutaneous injection in two studies (0, 30, or 100 mg/kg; 0 or 250 mg/kg) prior to and during mating and continuing throughout organogenesis, no adverse effects on embryofetal development were observed. The highest dose tested (250 mg/kg) was associated with a plasma exposure (C<span class=\"Sub\">ave, ss</span>) 38 or 18 times that in humans at the recommended human dose (RHD) for migraine  (120 mg) or episodic cluster headache (300 mg), respectively. Administration of galcanezumab-gnlm (0, 30, or 100 mg/kg) by subcutaneous injection to pregnant rabbits throughout the period of organogenesis produced no adverse effects on embryofetal development. The higher dose tested was associated with a plasma C<span class=\"Sub\">ave, ss</span> 64 or 29 times that in humans at 120 mg or 300 mg, respectively.</p><p>Administration of galcanezumab-gnlm (0, 30, or 250 mg/kg) by subcutaneous injection to rats throughout pregnancy and lactation produced no adverse effects on pre- and postnatal development. The higher dose tested was associated with a plasma C<span class=\"Sub\">ave, ss</span> 34 or 16 times that in humans at 120 mg or 300 mg, respectively.</p></div></div></div><div class=\"Section\" data-sectioncode=\"77290-5\"><a name=\"s26\"></a><a name=\"section-7.2\"></a><p></p><h2>8.2 Lactation</h2><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s27\"></a><a name=\"section-7.2.1\"></a><p></p><p class=\"First\"><span class=\"Underline\">Risk Summary</span></p><p>There are no data on the presence of galcanezumab-gnlm in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for EMGALITY and any potential adverse effects on the breastfed infant from EMGALITY or from the underlying maternal condition.</p></div></div><div class=\"Section\" data-sectioncode=\"34081-0\"><a name=\"s28\"></a><a name=\"section-7.3\"></a><p></p><h2>8.4 Pediatric Use</h2><p class=\"First\">Safety and effectiveness in pediatric patients have not been established.</p></div><div class=\"Section\" data-sectioncode=\"34082-8\"><a name=\"s29\"></a><a name=\"section-7.4\"></a><p></p><h2>8.5 Geriatric Use</h2><p class=\"First\">Clinical studies of EMGALITY did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.</p></div></section>",
    "description": "<section class=\"Section\" data-sectioncode=\"34089-3\"><a name=\"s30\"></a><a name=\"section-8\"></a><p></p><h1>11 DESCRIPTION</h1><p class=\"First\">Galcanezumab-gnlm is a humanized IgG4 monoclonal antibody specific for calcitonin-gene related peptide (CGRP) ligand. Galcanezumab-gnlm is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. Galcanezumab-gnlm is composed of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains and has an overall molecular weight of approximately 147 kDa.</p><p>EMGALITY (galcanezumab-gnlm) injection is a sterile, preservative-free, clear to opalescent and colorless to slightly yellow to slightly brown solution, for subcutaneous use. EMGALITY is supplied in a 1 mL single-dose prefilled pen to deliver 120 mg of galcanezumab-gnlm or a 1 mL single-dose prefilled syringe to deliver 100 mg or 120 mg of galcanezumab-gnlm. Each mL of solution contains  100 mg or 120 mg of galcanezumab-gnlm; L-histidine (0.5 mg); L-histidine hydrochloride monohydrate (1.5 mg); Polysorbate 80 (0.5 mg); Sodium Chloride (8.8 mg); Water for Injection, USP. The pH range is 5.3 - 6.3.</p></section>",
    "nonclinicalToxicology": "<section class=\"Section\" data-sectioncode=\"43680-8\"><a name=\"s43\"></a><a name=\"section-10\"></a><p></p><h1>13 NONCLINICAL TOXICOLOGY</h1><div class=\"Section\" data-sectioncode=\"34083-6\"><a name=\"s44\"></a><a name=\"section-10.1\"></a><p></p><h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s45\"></a><a name=\"section-10.1.1\"></a><p></p><p class=\"First\"><span class=\"Underline\">Carcinogenesis</span></p><p>The carcinogenic potential of galcanezumab-gnlm has not been assessed.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s46\"></a><a name=\"section-10.1.2\"></a><p></p><p class=\"First\"><span class=\"Underline\">Mutagenesis</span></p><p>Genetic toxicology studies of galcanezumab-gnlm have not been conducted.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s47\"></a><a name=\"section-10.1.3\"></a><p></p><p class=\"First\"><span class=\"Underline\">Impairment of Fertility</span></p><p>When galcanezumab-gnlm (0, 30, or 250 mg/kg) was administered to male rats by subcutaneous injection prior to and during mating, no adverse effects on fertility was observed. The higher dose tested was associated with a plasma exposure (C<span class=\"Sub\">ave, ss</span>) 8 or 4 times that in humans at the recommended human dose (RHD) for migraine (120 mg) or episodic cluster headache (300 mg), respectively. When galcanezumab-gnlm was administered to female rats by subcutaneous injection in two studies (0, 30, or 100 mg/kg; 0 or 250 mg/kg) prior to and during mating and continuing throughout organogenesis, no adverse effects on fertility were observed. The highest dose tested (250 mg/kg) was associated with a plasma C<span class=\"Sub\">ave, ss</span> 38 or 18 times that in humans at 120 mg or 300 mg, respectively.</p></div></div></section>",
    "instructionsForUse": "<section class=\"Section\" data-sectioncode=\"59845-8\"><a name=\"s62\"></a><a name=\"section-17\"></a><p></p><table class=\"Noautorules\" width=\"100%\"><col align=\"left\" width=\"100.000%\"/><tbody class=\"Headless\"><tr><td align=\"center\" valign=\"top\"><span class=\"Bold\">INSTRUCTIONS FOR USE</span></td></tr><tr><td align=\"center\" valign=\"top\"></td></tr><tr><td align=\"center\" valign=\"top\"><span class=\"Bold\">EMGALITY<span class=\"Sup\">®</span> (em-GAL-it-ē)</span></td></tr><tr><td align=\"center\" valign=\"top\"><span class=\"Bold\">(galcanezumab-gnlm)</span></td></tr><tr><td align=\"center\" valign=\"top\"><span class=\"Bold\">injection, for subcutaneous use</span></td></tr><tr><td align=\"center\" valign=\"top\"><span class=\"Bold\">Prefilled Syringe</span></td></tr><tr><td align=\"center\" valign=\"top\"><br/><a name=\"f09\"></a><img alt=\"Figure\n\" src=\"emgality-ifu-100mg-pfs-1-v1.jpg\"/></td></tr><tr><td align=\"left\" valign=\"top\"><span class=\"Bold\">This Instructions for Use is for patients with episodic cluster headache.</span></td></tr><tr><td align=\"left\" valign=\"top\"><ul class=\"Disc\"><li><span class=\"Bold\">If you are using EMGALITY for preventive treatment of migraine, there is a different Instructions for Use because the dose and number of syringes needed is different.</span></li></ul></td></tr><tr><td align=\"left\" valign=\"top\"><span class=\"Bold\">For subcutaneous injection only.</span></td></tr><tr><td align=\"left\" valign=\"top\"><span class=\"Bold\"> </span></td></tr><tr><td align=\"left\" valign=\"top\"><span class=\"Bold\">Before you use the EMGALITY prefilled syringe, read and carefully follow all the step-by-step instructions.</span></td></tr><tr><td align=\"left\" valign=\"top\"><span class=\"Bold\"> </span></td></tr><tr><td align=\"left\" valign=\"top\"><span class=\"Bold\">Important Information</span></td></tr><tr><td align=\"left\" valign=\"top\"><span class=\"Bold\"> </span></td></tr><tr><td align=\"left\" valign=\"top\"><ul class=\"Disc\"><li>Your healthcare provider or nurse should show you how to prepare and inject EMGALITY using the prefilled syringe. <span class=\"Bold\">Do not</span> inject yourself or someone else until you have been shown how to inject EMGALITY.</li></ul></td></tr><tr><td align=\"left\" valign=\"top\"><ul class=\"Disc\"><li>Keep this Instructions for Use and refer to it as needed.</li></ul></td></tr><tr><td align=\"left\" valign=\"top\"><ul class=\"Disc\"><li>Each EMGALITY prefilled syringe is for <span class=\"Bold\">one-time use only. Do not</span> share or reuse your EMGALITY prefilled syringe. You may give or get an infection.</li></ul></td></tr><tr><td align=\"left\" valign=\"top\"><ul class=\"Disc\"><li>Your healthcare provider may help you decide where on your body to inject your dose. You can also read the “<span class=\"Bold\"><a href=\"#p07\">Choose your injection site</a></span>” section of these instructions to help you choose which area can work best for you.</li></ul></td></tr><tr><td align=\"left\" valign=\"top\"><ul class=\"Disc\"><li>If you have vision problems, <span class=\"Bold\">do not</span> use EMGALITY prefilled syringe without help from a caregiver.</li></ul></td></tr><tr><td align=\"left\" valign=\"top\"><ul class=\"Disc\"><li>See “<span class=\"Bold\"><a href=\"#p01\">Storage and Handling Information</a></span>” for important storage information.</li></ul></td></tr></tbody></table><table class=\"Noautorules\" width=\"100%\"><col align=\"left\" width=\"100.000%\"/><tbody class=\"Headless\"><tr><td align=\"center\" valign=\"top\"><span class=\"Bold\">INSTRUCTIONS FOR USE</span></td></tr><tr><td align=\"left\" valign=\"top\"><span class=\"Bold\">Before you use the EMGALITY prefilled syringe, read and carefully follow all the step-by-step instructions.</span></td></tr><tr><td align=\"left\" valign=\"top\"><span class=\"Bold\">Parts of the EMGALITY Prefilled Syringe</span></td></tr><tr><td align=\"center\" valign=\"top\"><br/><a name=\"f10\"></a><img alt=\"Figure\n\" src=\"emgality-ifu-100mg-pfs-2-v1.jpg\"/></td></tr><tr><td align=\"left\" valign=\"top\"></td></tr></tbody></table><table class=\"Noautorules\" width=\"100%\"><col align=\"left\" width=\"34.500%\"/><col align=\"left\" width=\"65.500%\"/><tbody class=\"Headless\"><tr><td align=\"left\" colspan=\"2\" valign=\"top\"><span class=\"Bold\">Before You Get Started</span></td></tr><tr><td align=\"left\" valign=\"top\"><span class=\"Bold\">Take the Prefilled Syringes from the refrigerator</span></td><td align=\"left\" valign=\"top\">Take 3 EMGALITY prefilled syringes from the refrigerator.<br/></td></tr><tr><td align=\"left\" valign=\"top\"></td><td align=\"left\" valign=\"top\">Check your prescription.<br/><ul class=\"Disc\"><li>EMGALITY comes as a single-dose prefilled syringe.</li><li>You will need 3 prefilled syringes for each dose.</li></ul></td></tr><tr><td align=\"left\" valign=\"top\"></td><td align=\"left\" valign=\"top\"><span class=\"Bold\">Leave the needle caps on until you are ready to inject.</span></td></tr><tr><td align=\"left\" valign=\"top\"></td><td align=\"left\" valign=\"top\">Leave the prefilled syringes at room temperature for 30 minutes before injecting.</td></tr><tr><td align=\"left\" valign=\"top\"></td><td align=\"left\" valign=\"top\"><span class=\"Bold\">Do not</span> microwave the prefilled syringes, run hot water over them, or leave them in direct sunlight.</td></tr><tr><td align=\"left\" valign=\"top\"></td><td align=\"left\" valign=\"top\"><span class=\"Bold\">Do not</span> shake.</td></tr><tr><td align=\"left\" valign=\"top\"><span class=\"Bold\">Gather Supplies</span></td><td align=\"left\" valign=\"top\"><span class=\"Bold\">For each injection you will need: </span><br/><ul class=\"Disc\"><li>1 alcohol wipe</li><li>1 cotton ball or piece of gauze</li><li>1 sharps disposal container. See “<a href=\"#p02\">After You Inject Your Medicine</a>.”</li></ul></td></tr><tr><td align=\"left\" valign=\"top\"><span class=\"Bold\">Inspect the Prefilled Syringe and the medicine</span></td><td align=\"left\" valign=\"top\">Make sure you have the right medicine. The medicine inside should be clear. Its color may be colorless to slightly yellow to slightly brown.</td></tr><tr><td align=\"left\" rowspan=\"2\" valign=\"top\"></td><td align=\"left\" valign=\"top\"><span class=\"Bold\">Do not</span> use the prefilled syringe, and throw away (dispose of) as directed by your healthcare provider or pharmacist if:<br/><ul class=\"Disc\"><li>it looks damaged</li><li>the medicine is cloudy, is discolored, or has small particles</li><li>the Expiration Date (Exp.)  printed on the label has passed</li><li>the medicine is frozen</li></ul></td></tr><tr><td align=\"center\" valign=\"bottom\"><span class=\"Bold\">Expiration Date</span><br/><a name=\"f11\"></a><img alt=\"Figure\n\" src=\"emgality-ifu-100mg-pfs-3-v1.jpg\"/></td></tr><tr><td align=\"left\" valign=\"top\"><span class=\"Bold\">Prepare for injection</span></td><td align=\"left\" valign=\"top\">Wash your hands with soap and water before you inject your EMGALITY. Make sure a sharps disposal container is close by.</td></tr></tbody></table><table class=\"Noautorules\" width=\"100%\"><col align=\"left\" width=\"34.500%\"/><col align=\"left\" width=\"65.500%\"/><tbody class=\"Headless\"><tr><td align=\"left\" valign=\"top\"><p class=\"First\"><a name=\"p07\"></a><span class=\"Bold\">Choose your injection site</span></p></td><td align=\"left\" valign=\"top\"><br/>Your healthcare provider can help you choose the injection site that is best for you.</td></tr><tr><td align=\"left\" rowspan=\"6\" valign=\"top\"><br/><br/><a name=\"f30\"></a><img alt=\"Figure\n\" src=\"emgality-ifu-inj-sites-v2.jpg\"/></td><td align=\"left\" valign=\"top\"><ul class=\"Disc\"><li><span class=\"Bold\">You</span> may inject the medicine into your stomach area (abdomen). <span class=\"Bold\">Do not</span> inject within 2 inches of the belly button (navel).</li></ul></td></tr><tr><td align=\"left\" valign=\"top\"><ul class=\"Disc\"><li>You may inject the medicine into the front of your thighs. This area should be at least 2 inches above the knee and 2 inches below the groin.</li></ul></td></tr><tr><td align=\"left\" valign=\"top\"><ul class=\"Disc\"><li><span class=\"Bold\">Another person</span> may give you the injection in the back of your upper arm or buttocks.</li></ul></td></tr><tr><td align=\"left\" valign=\"top\"><ul class=\"Disc\"><li><span class=\"Bold\">Do not</span> inject in the exact same spot. For example, if your first injection was in your abdomen, your next injection could be in another area of your abdomen.</li></ul></td></tr><tr><td align=\"left\" valign=\"top\"><ul class=\"Disc\"><li>Do not inject into areas where the skin is tender, bruised, red, or hard.</li></ul></td></tr><tr><td align=\"left\" valign=\"top\"><ul class=\"Disc\"><li><span class=\"Bold\">Clean your injection site with an alcohol wipe. Let the injection site dry before you inject.</span></li></ul></td></tr></tbody></table><table class=\"Noautorules\" width=\"100%\"><col align=\"left\" width=\"6.219%\"/><col align=\"left\" width=\"2.679%\"/><col align=\"left\" width=\"40.632%\"/><col align=\"left\" width=\"24.315%\"/><col align=\"left\" width=\"26.155%\"/><tbody class=\"Headless\"><tr><td align=\"left\" rowspan=\"5\" valign=\"top\"><span class=\"Bold\">1</span></td><td align=\"left\" colspan=\"3\" valign=\"top\"><span class=\"Bold\">Uncap</span></td><td align=\"left\" rowspan=\"5\" valign=\"top\"><br/><a name=\"f14\"></a><img alt=\"Figure\n\" src=\"emgality-ifu-100mg-pfs-4-v1.jpg\"/></td></tr><tr><td align=\"left\" colspan=\"3\" valign=\"top\"><ul class=\"Disc\"><li><span class=\"Bold\">Leave the needle cap on until you are ready to inject.</span></li></ul></td></tr><tr><td align=\"left\" colspan=\"3\" valign=\"top\"><ul class=\"Disc\"><li> Pull the needle cap off and throw it away in your household trash.</li></ul></td></tr><tr><td align=\"left\" colspan=\"3\" valign=\"top\"><ul class=\"Disc\"><li><span class=\"Bold\">Do not</span> put the needle cap back on. You could damage the needle or stick yourself by accident.</li></ul></td></tr><tr><td align=\"left\" colspan=\"3\" valign=\"top\"><ul class=\"Disc\"><li><span class=\"Bold\">Do not</span> touch the needle.</li></ul></td></tr><tr><td align=\"left\" valign=\"top\"> </td><td align=\"left\" colspan=\"2\" valign=\"top\"></td><td align=\"left\" colspan=\"2\" valign=\"top\"></td></tr><tr><td align=\"left\" valign=\"top\"><span class=\"Bold\">2</span></td><td align=\"left\" colspan=\"3\" valign=\"top\"><span class=\"Bold\">Insert</span></td><td align=\"left\" rowspan=\"3\" valign=\"top\"><br/><a name=\"f15\"></a><img alt=\"Figure\n\" src=\"emgality-ifu-100mg-pfs-5-v1.jpg\"/></td></tr><tr><td align=\"left\" valign=\"top\"></td><td align=\"left\" colspan=\"3\" valign=\"top\"><ul class=\"Disc\"><li>Gently pinch and hold a fold of skin where you will inject.</li></ul></td></tr><tr><td align=\"left\" valign=\"top\"></td><td align=\"left\" colspan=\"3\" valign=\"top\"><ul class=\"Disc\"><li>Insert the needle at a 45-degree angle.</li></ul></td></tr><tr><td align=\"left\" valign=\"top\"> </td><td align=\"left\" colspan=\"2\" valign=\"top\"></td><td align=\"left\" colspan=\"2\" valign=\"top\"></td></tr><tr><td align=\"left\" rowspan=\"5\" valign=\"top\"><span class=\"Bold\">3</span></td><td align=\"left\" colspan=\"3\" valign=\"top\"><span class=\"Bold\">Inject</span></td><td align=\"left\" rowspan=\"3\" valign=\"top\"><br/><a name=\"f16\"></a><img alt=\"Figure\n\" src=\"emgality-ifu-100mg-pfs-6-v1.jpg\"/></td></tr><tr><td align=\"left\" colspan=\"3\" valign=\"top\"><ul class=\"Disc\"><li>Slowly push on the thumb pad to push the plunger all the way in until all the medicine is injected.<br/></li><li>The gray syringe plunger should be pushed all the way to the needle end of the syringe.</li></ul></td></tr><tr><td align=\"left\" colspan=\"3\" valign=\"top\"> </td></tr><tr><td align=\"left\" colspan=\"3\" valign=\"top\"><ul class=\"Disc\"><li>You should see the coral plunger rod show through the syringe body when the injection is complete as shown.</li><li>Remove the needle from your skin and gently let go of your skin.</li><li>If you have bleeding at the injection site, press a cotton ball or gauze over the injection site. Do not rub the injection site.</li><li><span class=\"Bold\">Do not</span> put the needle cap back on the prefilled syringe.</li></ul></td><td align=\"left\" colspan=\"2\" rowspan=\"2\" valign=\"top\"><a name=\"f17\"></a><img alt=\"Figure\n\" src=\"emgality-ifu-100mg-pfs-7-v1.jpg\"/><br/></td></tr><tr><td align=\"left\" valign=\"top\"></td></tr><tr><td align=\"left\" colspan=\"5\" valign=\"top\"></td></tr><tr><td align=\"left\" colspan=\"5\" valign=\"top\"><p class=\"First\"><a name=\"p02\"></a><span class=\"Bold\">After You Inject Your Medicine</span></p></td></tr><tr><td align=\"left\" colspan=\"5\" valign=\"top\"></td></tr><tr><td align=\"left\" colspan=\"5\" valign=\"top\"><span class=\"Bold\">Throw away the used prefilled syringe</span></td></tr><tr><td align=\"left\" colspan=\"3\" valign=\"top\"><ul class=\"Disc\"><li>Put the used EMGALITY prefilled syringe in an FDA-cleared sharps disposal container right away after use. <span class=\"Bold\">Do not</span> throw away (dispose of) the EMGALITY prefilled syringe in your household trash.</li></ul></td><td align=\"left\" colspan=\"2\" valign=\"top\"><br/><a name=\"f18\"></a><img alt=\"Figure\n\" src=\"emgality-ifu-100mg-pfs-8-v1.jpg\"/></td></tr><tr><td align=\"left\" colspan=\"5\" valign=\"top\"><ul class=\"Disc\"><li>If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:</li></ul></td></tr><tr><td align=\"left\" colspan=\"2\" valign=\"top\"></td><td align=\"left\" colspan=\"3\" valign=\"top\"><dl class=\"Disc\"><dt>–</dt><dd>made of a heavy-duty plastic,</dd></dl></td></tr><tr><td align=\"left\" colspan=\"2\" valign=\"top\"></td><td align=\"left\" colspan=\"3\" valign=\"top\"><dl class=\"Disc\"><dt>–</dt><dd>can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,</dd></dl></td></tr><tr><td align=\"left\" colspan=\"2\" valign=\"top\"></td><td align=\"left\" colspan=\"3\" valign=\"top\"><dl class=\"Disc\"><dt>–</dt><dd>upright and stable during use,</dd></dl></td></tr><tr><td align=\"left\" colspan=\"2\" valign=\"top\"></td><td align=\"left\" colspan=\"3\" valign=\"top\"><dl class=\"Disc\"><dt>–</dt><dd>leak-resistant, and</dd></dl></td></tr><tr><td align=\"left\" colspan=\"2\" valign=\"top\"></td><td align=\"left\" colspan=\"3\" valign=\"top\"><dl class=\"Disc\"><dt>–</dt><dd>properly labeled to warn of hazardous waste inside the container.</dd></dl></td></tr><tr><td align=\"left\" colspan=\"5\" valign=\"top\"><ul class=\"Disc\"><li>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal.</li></ul></td></tr><tr><td align=\"left\" colspan=\"5\" valign=\"top\"><ul class=\"Disc\"><li><span class=\"Bold\">Do not</span> recycle your used sharps disposal container.</li></ul></td></tr><tr><td align=\"left\" colspan=\"5\" valign=\"top\"><br/>For each of the 3 injections, repeat all instructions with a new prefilled syringe.</td></tr></tbody></table><table class=\"Noautorules\" width=\"100%\"><col align=\"left\" width=\"4.165%\"/><col align=\"left\" width=\"47.917%\"/><col align=\"left\" width=\"47.917%\"/><tbody class=\"Headless\"><tr><td align=\"left\" colspan=\"3\" valign=\"top\"><span class=\"Bold\">Commonly Asked Questions</span></td></tr><tr><td align=\"left\" colspan=\"3\" valign=\"top\"></td></tr><tr><td align=\"left\" valign=\"top\"><span class=\"Bold\">Q.</span></td><td align=\"left\" colspan=\"2\" valign=\"top\"><span class=\"Bold\">What if I see air bubbles in my EMGALITY prefilled syringe?</span></td></tr><tr><td align=\"left\" valign=\"top\"><span class=\"Bold\">A.</span></td><td align=\"left\" colspan=\"2\" valign=\"bottom\">It is normal to have air bubbles in the prefilled syringe. EMGALITY is injected under your skin (subcutaneous injection), so these air bubbles will not harm you.</td></tr><tr><td align=\"left\" valign=\"top\"></td><td align=\"left\" colspan=\"2\" valign=\"top\"></td></tr><tr><td align=\"left\" valign=\"top\"><span class=\"Bold\">Q.</span></td><td align=\"left\" colspan=\"2\" valign=\"top\"><span class=\"Bold\">What if there is a drop of liquid on the tip of the needle when I remove the needle cap?</span></td></tr><tr><td align=\"left\" valign=\"top\"><span class=\"Bold\">A.</span></td><td align=\"left\" colspan=\"2\" valign=\"bottom\">It is okay to see a drop of liquid on the tip of the needle.</td></tr><tr><td align=\"left\" valign=\"top\"></td><td align=\"left\" colspan=\"2\" valign=\"top\"></td></tr><tr><td align=\"left\" valign=\"top\"><span class=\"Bold\">Q.</span></td><td align=\"left\" colspan=\"2\" valign=\"top\"><span class=\"Bold\">What if I cannot push in the plunger?</span></td></tr><tr><td align=\"left\" valign=\"top\"><span class=\"Bold\">A.</span></td><td align=\"left\" colspan=\"2\" valign=\"top\">If the plunger is stuck or damaged:</td></tr><tr><td align=\"left\" valign=\"bottom\"></td><td align=\"left\" colspan=\"2\" valign=\"bottom\"><ul class=\"Disc\"><li><span class=\"Bold\">Do not</span> continue to use the syringe</li></ul></td></tr><tr><td align=\"left\" valign=\"bottom\"></td><td align=\"left\" colspan=\"2\" valign=\"bottom\"><ul class=\"Disc\"><li>Remove the needle from your skin</li></ul></td></tr><tr><td align=\"left\" valign=\"bottom\"></td><td align=\"left\" colspan=\"2\" valign=\"bottom\"><ul class=\"Disc\"><li>Dispose of the syringe and get a new one</li></ul></td></tr><tr><td align=\"left\" valign=\"top\"></td><td align=\"left\" colspan=\"2\" valign=\"top\"></td></tr><tr><td align=\"left\" valign=\"top\"><span class=\"Bold\">Q.</span></td><td align=\"left\" colspan=\"2\" valign=\"top\"><span class=\"Bold\">What if there is a drop of liquid or blood on my skin after my injection?</span></td></tr><tr><td align=\"left\" valign=\"top\"><span class=\"Bold\">A.</span></td><td align=\"left\" colspan=\"2\" valign=\"top\">This is normal. Press a cotton ball or gauze over the injection site. <span class=\"Bold\">Do not</span> rub the injection site.</td></tr><tr><td align=\"left\" valign=\"top\"></td><td align=\"left\" colspan=\"2\" valign=\"top\"></td></tr><tr><td align=\"left\" valign=\"top\"><span class=\"Bold\">Q.</span></td><td align=\"left\" colspan=\"2\" valign=\"top\"><span class=\"Bold\">How can I tell if my injection is complete?</span></td></tr><tr><td align=\"left\" valign=\"top\"><span class=\"Bold\">A.</span></td><td align=\"left\" colspan=\"2\" valign=\"top\">When your injection is complete:</td></tr><tr><td align=\"left\" valign=\"bottom\"></td><td align=\"left\" colspan=\"2\" valign=\"bottom\"><ul class=\"Disc\"><li>The coral plunger rod should show through the body of the syringe.</li></ul></td></tr><tr><td align=\"left\" valign=\"bottom\"></td><td align=\"left\" colspan=\"2\" valign=\"bottom\"><ul class=\"Disc\"><li>The gray syringe plunger should be pushed all the way to the needle end of the syringe.</li></ul></td></tr><tr><td align=\"left\" valign=\"top\"></td><td align=\"left\" colspan=\"2\" valign=\"top\"></td></tr><tr><td align=\"left\" colspan=\"3\" valign=\"top\"><span class=\"Bold\">If you have more questions about how to use the EMGALITY prefilled syringe:</span></td></tr><tr><td align=\"left\" valign=\"bottom\"></td><td align=\"left\" valign=\"bottom\"><ul class=\"Disc\"><li>Call your healthcare provider</li></ul></td><td align=\"center\" rowspan=\"3\" valign=\"bottom\"><br/><a name=\"f19\"></a><img alt=\"Figure\n\" src=\"emgality-qr-v1.jpg\"/></td></tr><tr><td align=\"left\" valign=\"bottom\"></td><td align=\"left\" valign=\"bottom\"><ul class=\"Disc\"><li>Call 1-833-EMGALITY (1-833-364-2548)</li></ul></td></tr><tr><td align=\"left\" valign=\"bottom\"></td><td align=\"left\" valign=\"bottom\"><ul class=\"Disc\"><li>Visit www.emgality.com</li></ul></td></tr></tbody></table><table class=\"Noautorules\" width=\"100%\"><col align=\"left\" width=\"54.550%\"/><col align=\"left\" width=\"45.450%\"/><tbody class=\"Headless\"><tr><td align=\"left\" valign=\"top\"><p class=\"First\"><a name=\"p01\"></a><span class=\"Bold\">Storage and Handling Information</span></p></td><td align=\"right\" valign=\"top\"></td></tr><tr><td align=\"left\" colspan=\"2\" valign=\"top\"><ul class=\"Disc\"><li>Store your prefilled syringes in the refrigerator between 36ºF to 46ºF (2ºC to 8ºC).</li></ul></td></tr><tr><td align=\"left\" colspan=\"2\" valign=\"top\"><ul class=\"Disc\"><li>Your prefilled syringes may be stored out of the refrigerator in the original carton at temperatures up to 86ºF (30ºC) for up to 7 days. After storing out of the refrigerator, <span class=\"Bold\">do not</span> place EMGALITY back in the refrigerator.</li></ul></td></tr><tr><td align=\"left\" colspan=\"2\" valign=\"top\"><ul class=\"Disc\"><li><span class=\"Bold\">Do not</span> freeze your prefilled syringes.</li></ul></td></tr><tr><td align=\"left\" colspan=\"2\" valign=\"top\"><ul class=\"Disc\"><li>Keep your prefilled syringes in the carton they come in to protect them from light until time of use.</li></ul></td></tr><tr><td align=\"left\" colspan=\"2\" valign=\"top\"><ul class=\"Disc\"><li><span class=\"Bold\">Do not</span> shake your prefilled syringes.</li></ul></td></tr><tr><td align=\"left\" colspan=\"2\" valign=\"top\"><ul class=\"Disc\"><li>Throw away your prefilled syringes if any of the above conditions are not followed.</li></ul></td></tr><tr><td align=\"left\" colspan=\"2\" valign=\"top\"><ul class=\"Disc\"><li><span class=\"Bold\">Keep your prefilled syringes and all medicines out of the reach of children.</span></li></ul></td></tr><tr><td align=\"left\" valign=\"top\"> </td><td align=\"left\" valign=\"top\"></td></tr><tr><td align=\"left\" colspan=\"2\" valign=\"top\"><span class=\"Bold\">Read the full Prescribing Information and Patient Information for EMGALITY inside this box to learn more about your medicine.</span></td></tr></tbody></table><table class=\"Noautorules\" width=\"100%\"><col align=\"left\" width=\"54.000%\"/><col align=\"left\" width=\"45.000%\"/><col align=\"left\" width=\"1.000%\"/><tbody class=\"Headless\"><tr><td align=\"left\" colspan=\"3\" valign=\"top\"><br/>This Instructions for Use has been approved by the U.S. Food and Drug Administration.<br/></td></tr><tr><td align=\"left\" colspan=\"3\" valign=\"top\">Eli Lilly and Company </td></tr><tr><td align=\"left\" colspan=\"3\" valign=\"top\">Indianapolis, IN 46285, USA</td></tr><tr><td align=\"left\" colspan=\"3\" valign=\"top\">US License Number 1891</td></tr><tr><td align=\"left\" colspan=\"3\" valign=\"top\"><br/>EMGALITY<span class=\"Sup\">®</span> is a registered trademark of Eli Lilly and Company.</td></tr><tr><td align=\"left\" colspan=\"3\" valign=\"top\"><br/>Copyright © 2019, Eli Lilly and Company. All rights reserved.</td></tr><tr><td align=\"left\" colspan=\"3\" valign=\"top\"><br/>Issued: 06/2019</td></tr><tr><td align=\"left\" colspan=\"3\" valign=\"top\"><br/>EMG-0001-PFS-100MG-IFU-20190604</td></tr></tbody></table></section>",
    "mechanismOfAction": "<section class=\"Section\" data-sectioncode=\"43679-0\"><a name=\"s32\"></a><a name=\"section-9.1\"></a><p></p><h2>12.1 Mechanism of Action</h2><p class=\"First\">Galcanezumab-gnlm is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.</p></section>",
    "contraindications": "<section class=\"Section\" data-sectioncode=\"34070-3\"><a name=\"s11\"></a><a name=\"section-4\"></a><p></p><h1>4 CONTRAINDICATIONS</h1><p class=\"First\">EMGALITY is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients <span class=\"Italics\">[see Warnings and Precautions (<a href=\"#s13\">5.1</a>)]</span>.</p></section>",
    "highlights": {
      "dosageAndAdministration": "<div><ul class=\"Disc\"><li>For subcutaneous use only. (<a href=\"#s6\">2.1</a>, <a href=\"#s8\">2.2</a>, <a href=\"#s9\">2.3</a>)</li><li>Migraine recommended dosage: 240 mg loading dose (administered as two consecutive injections of 120 mg each), followed by monthly doses of 120 mg. (<a href=\"#s6\">2.1</a>)</li><li>Episodic cluster headache recommended dosage: 300 mg (administered as three consecutive injections of 100 mg each) at the onset of the cluster period, and then monthly until the end of the cluster period. (<a href=\"#s8\">2.2</a>)</li><li>Administer in the abdomen, thigh, back of the upper arm, or buttocks subcutaneously. (<a href=\"#s9\">2.3</a>)</li></ul></div>"
    }
  }
}